The Board of Directors resolved to hold 2018 Annual General Meeting

Clarification on the news articles by Commercial Times, United Daily, etc.

FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

Shilin District Court deny OBI's request to submit the case for trial

OBI Pharma Inc. to attend the investor conference on new drug development, hosted by Masterlink Securities

Capital increase for new shares to transfer to AP Biosciences, Inc.

OBI Pharma Inc. to attend the 36th J.P. Morgan Annual Healthcare Conference

OBI Pharma Inc. to attend Citi's 2017 Global Healthcare Conference

OBI Pharma Inc. to attend the 2017 Asia Pacific Healthcare Forum, hosted by Goldman Sachs

SFIPC and OBI jointly agreed to withdraw the proceedings on Civil case regarding the dismissal of the Chairman of the company.